



Moderna to Provide Business and Pipeline Updates at the 2019 J.P. Morgan Healthcare Conference

January 2, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 2, 2019-- Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced today that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at this year's 37th annual J.P. Morgan Healthcare Conference.

Mr. Bancel's presentation will take place on Tuesday, January 8, 2019 at 10:30 a.m. PT in the Colonial Room at The Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session. A live webcast of both the presentation and question and answer session can be accessed on the investors section of Moderna's website at investors.modernatx.com. A replay of the webcast also will be archived on Moderna's website for up to 30 days following the presentation.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body's cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. Moderna's platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca and Merck & Co., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense; the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been ranked in the top ten of *Science's* list of top biopharma industry employers for the past four years. To learn more, visit www.modernatx.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190102005536/en/>

Source: Moderna, Inc.

Media:

Jason Glashow
Head of Corporate Communications
617-674-5648
jason.glashow@modernatx.com

Investors:

Lorence Kim
Chief Financial Officer
617-209-5849
lorence.kim@modernatx.com